Cargando…

ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans

BACKGROUND: Cortisol and corticosterone both circulate in human plasma and, due to differing export by ATP-binding cassette (ABC) transporters, may exert differential cellular effects. ABCB1 (expressed in brain) exports cortisol not corticosterone while ABCC1 (expressed in adipose and skeletal muscl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyle, Catriona J., Nixon, Mark, Homer, Natalie Z.M., Morgan, Ruth A., Andrew, Ruth, Stimson, Roland H., Walker, Brian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861854/
https://www.ncbi.nlm.nih.gov/pubmed/34990712
http://dx.doi.org/10.1016/j.metabol.2021.155118
_version_ 1784654953059450880
author Kyle, Catriona J.
Nixon, Mark
Homer, Natalie Z.M.
Morgan, Ruth A.
Andrew, Ruth
Stimson, Roland H.
Walker, Brian R.
author_facet Kyle, Catriona J.
Nixon, Mark
Homer, Natalie Z.M.
Morgan, Ruth A.
Andrew, Ruth
Stimson, Roland H.
Walker, Brian R.
author_sort Kyle, Catriona J.
collection PubMed
description BACKGROUND: Cortisol and corticosterone both circulate in human plasma and, due to differing export by ATP-binding cassette (ABC) transporters, may exert differential cellular effects. ABCB1 (expressed in brain) exports cortisol not corticosterone while ABCC1 (expressed in adipose and skeletal muscle) exports corticosterone not cortisol. We hypothesised that ABCC1 inhibition increases corticosteroid receptor occupancy by corticosterone but not cortisol in humans. METHODS: A randomised double-blind crossover study was conducted in 14 healthy men comparing placebo and ABCC1 inhibitor probenecid. Blood sampling, including from veins draining adipose and muscle, was undertaken before and after administration of mineralocorticoid receptor antagonist potassium canrenoate and glucocorticoid receptor antagonist mifepristone (RU486). RESULTS: During placebo, systemic plasma cortisol and corticosterone concentrations increased promptly after canrenoate. Cortisol uptake was detected from adipose but not muscle following canrenoate + RU486. Probenecid significantly increased systemic cortisol concentrations, and tended to increase corticosterone and ACTH concentrations, after combined receptor antagonism but had no effects on net glucocorticoid balance in either adipose or muscle. Using quantitative PCR in brain bank tissue, ABCC1 expression was 5-fold higher in human pituitary than hypothalamus and hippocampus. ABCB1 was more highly expressed in hypothalamus compared to pituitary. CONCLUSIONS: Although displacement of corticosterone and/or cortisol from receptors in adipose and skeletal muscle could not be measured with sufficient precision to detect effects of probenecid, ABCC1 inhibition induced a greater incremental activation of the hypothalamic-pituitary-adrenal axis after combined receptor blockade, consistent with ABCC1 exporting corticosterone from the pituitary and adding to the evidence that ABC transporters modulate tissue glucocorticoid sensitivity.
format Online
Article
Text
id pubmed-8861854
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-88618542022-03-01 ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans Kyle, Catriona J. Nixon, Mark Homer, Natalie Z.M. Morgan, Ruth A. Andrew, Ruth Stimson, Roland H. Walker, Brian R. Metabolism Article BACKGROUND: Cortisol and corticosterone both circulate in human plasma and, due to differing export by ATP-binding cassette (ABC) transporters, may exert differential cellular effects. ABCB1 (expressed in brain) exports cortisol not corticosterone while ABCC1 (expressed in adipose and skeletal muscle) exports corticosterone not cortisol. We hypothesised that ABCC1 inhibition increases corticosteroid receptor occupancy by corticosterone but not cortisol in humans. METHODS: A randomised double-blind crossover study was conducted in 14 healthy men comparing placebo and ABCC1 inhibitor probenecid. Blood sampling, including from veins draining adipose and muscle, was undertaken before and after administration of mineralocorticoid receptor antagonist potassium canrenoate and glucocorticoid receptor antagonist mifepristone (RU486). RESULTS: During placebo, systemic plasma cortisol and corticosterone concentrations increased promptly after canrenoate. Cortisol uptake was detected from adipose but not muscle following canrenoate + RU486. Probenecid significantly increased systemic cortisol concentrations, and tended to increase corticosterone and ACTH concentrations, after combined receptor antagonism but had no effects on net glucocorticoid balance in either adipose or muscle. Using quantitative PCR in brain bank tissue, ABCC1 expression was 5-fold higher in human pituitary than hypothalamus and hippocampus. ABCB1 was more highly expressed in hypothalamus compared to pituitary. CONCLUSIONS: Although displacement of corticosterone and/or cortisol from receptors in adipose and skeletal muscle could not be measured with sufficient precision to detect effects of probenecid, ABCC1 inhibition induced a greater incremental activation of the hypothalamic-pituitary-adrenal axis after combined receptor blockade, consistent with ABCC1 exporting corticosterone from the pituitary and adding to the evidence that ABC transporters modulate tissue glucocorticoid sensitivity. W.B. Saunders 2022-03 /pmc/articles/PMC8861854/ /pubmed/34990712 http://dx.doi.org/10.1016/j.metabol.2021.155118 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kyle, Catriona J.
Nixon, Mark
Homer, Natalie Z.M.
Morgan, Ruth A.
Andrew, Ruth
Stimson, Roland H.
Walker, Brian R.
ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans
title ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans
title_full ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans
title_fullStr ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans
title_full_unstemmed ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans
title_short ABCC1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans
title_sort abcc1 modulates negative feedback control of the hypothalamic-pituitary-adrenal axis in vivo in humans
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861854/
https://www.ncbi.nlm.nih.gov/pubmed/34990712
http://dx.doi.org/10.1016/j.metabol.2021.155118
work_keys_str_mv AT kylecatrionaj abcc1modulatesnegativefeedbackcontrolofthehypothalamicpituitaryadrenalaxisinvivoinhumans
AT nixonmark abcc1modulatesnegativefeedbackcontrolofthehypothalamicpituitaryadrenalaxisinvivoinhumans
AT homernataliezm abcc1modulatesnegativefeedbackcontrolofthehypothalamicpituitaryadrenalaxisinvivoinhumans
AT morganrutha abcc1modulatesnegativefeedbackcontrolofthehypothalamicpituitaryadrenalaxisinvivoinhumans
AT andrewruth abcc1modulatesnegativefeedbackcontrolofthehypothalamicpituitaryadrenalaxisinvivoinhumans
AT stimsonrolandh abcc1modulatesnegativefeedbackcontrolofthehypothalamicpituitaryadrenalaxisinvivoinhumans
AT walkerbrianr abcc1modulatesnegativefeedbackcontrolofthehypothalamicpituitaryadrenalaxisinvivoinhumans